If the criterion for naming the potential partner is the approaching patent cliff then the possibilities widens, a lot:
https://www.biopharmadive.com/news/pharma-patent-cliff-biologic-drugs-humira-keytruda/642660/
this BF in particular is getting on the radar of some US senators for trying to re-cook their patent for their cash cow:
https://www.fiercepharma.com/pharma/sen-warren-urges-us-pto-closely-scrutinize-mercks-patent-efforts-keytruda
Ann: New PAT-DX3 data demonstrates synthetic lethality, page-26
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 6881369 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1994916 | 4 |
View Market Depth
| Last trade - 16.12pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.7¢ | 0.7¢ | 70000 | ||
| Last updated 12.54pm 14/05/2024 ? | |||||
| PAB (ASX) Chart |
Day chart unavailable